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Objective: To develop recommendations for the diagnosis, management and treatment of
lupus nephritis in Brazil.
Method: Extensive literature review with a selection of papers based on the strength of scien-
tiﬁc  evidence and opinion of the Commission on Systemic Lupus Erythematosus members,
Brazilian Society of Rheumatology.
Results and conclusions: (1) Renal biopsy should be performed whenever possible and if this
procedure is indicated; and, when the procedure is not possible, the treatment should be
guided with the inference of histologic class. (2) Ideally, measures and precautions should be
implemented before starting treatment, with emphasis on attention to the risk of infection.
(3)  Risks and beneﬁts of treatment should be shared with the patient and his/her family. (4)
The  use of hydroxychloroquine (preferably) or chloroquine diphosphate is recommended forall  patients (unless contraindicated) during induction and maintenance phases. (5) The eval-
uation of the effectiveness of treatment should be made with objective criteria of response
(complete remission/partial remission/refractoriness). (6) Angiotensin-converting enzyme
inhibitors and/or angiotensin receptor blockers are recommended as antiproteinuric agents
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for all patients (unless contraindicated). (7) The identiﬁcation of clinical and/or labora-
tory signs suggestive of proliferative or membranous glomerulonephritis should indicate
an  immediate implementation of speciﬁc therapy, including corticosteroids and an
immunosuppressive agent, even though histological conﬁrmation is not possible. (8)
Immunosuppressives must be used during at least 36 months, but these medications can
be  kept for longer periods. Its discontinuation should only be done when the patient could
achieve and maintain a sustained and complete remission. (9) Lupus nephritis should be
considered as refractory when a full or partial remission is not achieved after 12 months
of  an appropriate treatment, when a new renal biopsy should be considered to assist in
identifying the cause of refractoriness and in the therapeutic decision.
© 2014 Elsevier Editora Ltda. All rights reserved.
Consenso  da  Sociedade  Brasileira  de  Reumatologia  para  o  diagnóstico,
manejo  e  tratamento  da  nefrite  lúpica
Palavras-chave:
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Terapêutica
Brasil
Consenso
r  e  s  u  m  o
Objetivo: Elaborar recomendac¸ões para o diagnóstico, manejo e tratamento da nefrite lúpica
no  Brasil.
Método: Revisão extensa da literatura com selec¸ão dos artigos com base na forc¸a de evidência
cientíﬁca e opinião dos membros da Comissão de Lúpus Eritematoso Sistêmico da Sociedade
Brasileira de Reumatologia.
Resultados e conclusões: 1) A biópsia renal deve ser feita sempre que possível e houver
indicac¸ão  e quando não for possível, o tratamento deve ser orientado com base na infer-
ência da classe histológica. 2) Devem ser implementados medidas e cuidados idealmente
antes do início do tratamento, com ênfase na atenc¸ão ao risco de infecc¸ão. 3) Devem-se
compartilhar riscos e benefícios do tratamento com os pacientes e familiares. 4) O uso
da  hidroxicloroquina (preferencialmente) ou difosfato de cloroquina é recomendado para
todos os pacientes (exceto contraindicac¸ão) durante as fases de induc¸ão e manutenc¸ão.
5)  A avaliac¸ão da eﬁcácia do tratamento deve ser feita com critérios objetivos de resposta
(remissão completa/remissão parcial/refratariedade). 6) Os inibidores da enzima conversora
da angiotensina ou bloqueadores dos receptores da angiotensina são recomendados como
antiproteinúricos para todos os pacientes (exceto contraindicac¸ão). 7) A identiﬁcac¸ão de
sinais clínicos e/ou laboratoriais sugestivos de GN proliferativa ou membranosa deve indicar
início imediato de terapia especíﬁca incluindo corticosteroides e agente imunossupressor,
mesmo que não seja possível comprovac¸ão histológica. 8) O tempo de uso dos imunossu-
pressores deve ser no mínimo de 36 meses, mas eles podem ser mantidos por períodos mais
longos. A sua suspensão só deve ser feita quando o paciente atingir e mantiver remissão
completa sustentada. 9) Deve-se considerar NL refratária quando a remissão completa ou
parcial não for alcanc¸ada após 12 meses de tratamento adequado, quando uma nova bióp-
sia renal deve ser considerada para auxiliar na identiﬁcac¸ão da causa da refratariedade e
decisão terapêutica.
© 2014 Elsevier Editora Ltda. Todos os direitos reservados.Introduction
Systemic lupus erythematosus (SLE) is a chronic autoimmune
inﬂammatory disease which ethiopathogenesis involves mul-
tiple genes and hormonal and environmental factors. SLE is
a pleomorphic disease with wide phenotypic variability of
presentation, severity and clinical course, usually progres-
sing with periods of activity and remission. Most patients
exhibit a relatively benign course, but overall survival is lower,
when compared to the general population, with a standard-
ized mortality ratio from 2.4 to 6.4.1 The main causes of
death are infection, disease activity, cardiovascular disease,kidney damage and cancer (A).1–3 The morbidity and mortal-
ity are particularly high in patients with renal impairment
(C).2–9 Glomerulonephritis (GN) is the most frequent cause for
the use of high doses of corticosteroids (CS) and immuno-
suppressants, being also the condition that requires more
hospitalizations and the main factor related to increased mor-
tality. Progression to end stage renal disease, or more  recently,
established renal failure (ERF), deﬁned by a glomerular ﬁl-
tration rate (GFR) ≤15 mL/min, requiring renal replacement
therapy, occurs in 10–30% of patients, especially those with
proliferative glomerulonephritis (PGN).10,11 At the same time,
in SLE patients on dialysis, the 5-year survival is lower than
that of individuals on dialysis without SLE.9
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The renal involvement in SLE occurs clinically in about
0% of patients and can determine tubular, interstitial, vas-
ular and glomerular changes; but is the involvement of
he latter compartment that determines most of the signs
nd symptoms of lupus nephritis (LN) (B).12 Similarly to the
emonstrations in other systems, LN also shows different
egrees of severity, with periods of activity and remission,
hich determine the choice of therapeutic agents to be used
B).13 In clinical practice, it is not always possible to perform
 kidney biopsy, although this is a relatively simple procedure
hen performed by experienced professionals.14 The biopsy
llows the recognition of diagnostic and prognostic markers
hat may inﬂuence the therapeutic choice. For patients not
ndergoing a kidney biopsy and for all patients in the course
f evolution, clinical and laboratory markers that help charac-
erize the severity and activity of GN are used (B),15 guiding
he use of immunomodulatory and/or immunosuppressant
gents.
The main goal of the treatment is to achieve a complete
emission (CR), which is associated with a good long-term
rognosis.11,16 However, despite current therapeutic regimens,
ess than 50% of patients with LN achieve CR after the ﬁrst 6
onths of treatment (B).17–19
This consensus aims to present the main recommenda-
ions for the clinical management of LN, involving diagnosis,
rognosis, treatment (induction and maintenance), care dur-
ng the use of pharmacological agents, immunosuppression-
djuvant therapy, refractory case approaches and identiﬁca-
ion of associated comorbidities, all contextualized to the
eality of our country.
aterials  and  methods
his consensus was developed after a systematic review of
he literature, in association with the opinion of 13 rheuma-
ologists with clinical experience in LN, 11 of them being
embers of the SLE Commission of SBR, besides two guests
CAAS and EMNA). The systematic review of the literature,
ncluding the prior selection of a number of issues previously
dentiﬁed by the working group and the voting of recom-
endations, was performed according to a modiﬁed Delphi
ethod. The databases included MEDLINE, SciELO, PubMed
nd EMBASE until November 2013. After consideration of the
ata obtained in the literature, the participants expressed
heir opinion on each topic in discussions via Internet, and
oted on recommendations conﬁdentially. Voting occurred in
ace-to-face meetings held in May and July 2014 in a hierar-
hical manner, according to the following alternatives: (a) I
ompletely agree; (b) I agree with some reservation; (c) I agree
ith many  reservations; (d) I reject with reservations; (e) I com-
letely reject. In cases of non-agreement of at least 70% of
he participants (for options a, b or c), new discussions were
eld, followed by adjustments for the recommendation and
 new round of voting, until this minimum percentage was
eached. For each recommendation, the percentages of agree-
ent among the participants were informed. When possible,
he levels of evidence were expressed according to the Oxford
lassiﬁcation:2 0 1 5;5  5(1):1–21 3
A –Experimental or observational studies of greater consis-
tency.
B – Experimental or observational studies of lower consis-
tency.
C – Case reports (non-controlled studies).
D – Opinion without critical evaluation, based on consen-
suses, physiological studies or animal models.
Renal  biopsy
Recently, the ACR (American College of Rheumatology)20
and the EULAR (European League Against Rheumatism), in
combination with two  European groups of Nephrology (Euro-
pean Renal Association – European Dialysis and Transplant
Association)21 published recommendations for the manage-
ment of SLE patients with renal involvement, based on
histological ﬁndings.
A renal biopsy should be performed whenever possible,20,21
considering that clinical, immunological and laboratory
parameters are not predictors of the histological ﬁndings.20–22
This procedure may better guide the treatment and prognosis,
and should always be performed by experienced and qualiﬁed
professionals.23
EULAR recommends obtaining a renal biopsy whenever
there is any sign of renal involvement, especially proteinuria
≥0.5 g/24 h accompanied by glomerular dysmorphic hema-
turia and/or cellular casts (C).21 ACR recommends a biopsy
(unless strongly contraindicated) whenever there are signs of
renal involvement with an elevated serum creatinine with no
apparent cause (not related to SLE), proteinuria ≥1.0 g/24 h or
an isolated proteinuria ≥0.5 g/24 h associated with hematuria
and/or cellular casts (C).20 When GFR <30 mL/min, the decision
to obtain a biopsy should take into consideration the normal
kidney size (>9 cm)  and/or evidence of active renal disease.21
The histological pattern of LN should follow the new deﬁ-
nitions, revised by international societies of nephrology and
pathology,24,25 known as the classiﬁcation of lupus nephri-
tis of the International Society of Nephrology/Renal Pathology
Society 2003 (ISN/RPS 2003) (C) (Table 1). According to these
guidelines, glomeruli and the tubulointerstitial region should
be evaluated, with descriptions of activity and chronicity,
besides the vascular component that is usually associated
with antiphospholipid antibody syndrome (APS) (C).20,21,24,25 A
sample is considered adequate if it has more  than 8 glomeruli,
and immunoﬂuorescence or immunohistochemistry is rec-
ommended to identify complement and immunoglobulin
deposits. If possible, electron microscopy should also be per-
formed, because this examination facilitates the evaluation of
proliferative and membranous lesions (C).21,24,25
Usually there is no need for a repeat biopsy in the case
of new outbreaks of renal activity26,27 because this procedure
does not provide additional information about renal outcomes
in the long term.28 However, in patients without adequate
response to treatment, repeat biopsy may help in the iden-
tiﬁcation of the cause of refractoriness20,21,29 and assist in
therapeutic decision.21,29In this consensus, we recommend obtaining a renal biopsy
whenever the patient exhibits an elevated serum creatinine
with no apparent cause, and when this ﬁnding is potentially
associated with SLE, with isolated proteinuria ≥1.0 g/24 h or
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Table 1 – Classiﬁcation of the International Society of Nephrology/Renal Pathology Society 2003 for lupus nephritis.
Class I – minimal mesangial LN
Normal glomeruli under light microscopy (LM), but with immune deposits under immunoﬂuorescence (IF).
Class II – proliferative mesangial LN
Pure mesangial hypercellularity of any degree or mesangial matrix expansion under MO with immune deposits in the mesangium. There may
be few and isolated subepithelial or subendothelial deposits visible under IF or electron microscopy (EM), but not under OM.
Class III – focal LN
Active or inactive, focal, segmental or global, endo- and extracapillary glomerulonephritis (GN) involving <50% of all glomeruli, typically with
subendothelial immune deposits, with or without mesangial alterations. It is further classiﬁed into: A, active; A/C, active/chronic; C, inactive
chronic.
Class IV – diffuse LN
Active or inactive, segmental or global, endo and extracapillary glomerulonephritis (GN) involving ≥50% of all glomeruli, typically with
subendothelial immune deposits, with or without mesangial alterations. It is divided into segmental diffuse (IV-S), in which ≥50% of
glomeruli involved present segmental lesions (involving less than half of the tuft) and into global diffuse (IV-G), in which ≥50% of glomeruli
involved have global lesions (involving more than half of the tuft). This class includes cases with diffuse wire-loop deposits with little or no
glomerular proliferation. It is further classiﬁed into: A, active; A/C, active/chronic; C, inactive chronic.
Class V – membranous LN
Global and segmental subepithelial immune deposits or its morphological sequelae under OM and IF or EM, with or without mesangial changes.
May occur in combination with class III or IV.
Class VI – advanced sclerosis
Global glomerular sclerosis in ≥90%, with no residual activity.
lectroAdapted from Weening et al., 2004.24,25
AB, antibody; GN, glomerulonephritis; IF, immunoﬂuorescence; EM, e
proteinuria ≥0.5 g/24 h associated with glomerular dysmor-
phic hematuria and/or the presence of cellular casts. These
changes must be conﬁrmed in a second biopsy (Table 2).
Evaluation  of  LN  without  renal  biopsy:  inference  of
histological  class  for  a  therapeutic  decision  and
progression  assessment
In most cases of NL, clinical, serologic and laboratory tests
cannot accurately predict the histological ﬁndings, nor could
they differentiate other possible causes of renal disease.20–22
However, this dataset can be very useful in the clinical moni-
toring of nephritis and, in particular, assisting in the diagnosis
of renal disease activity.30
The active urinary sediment, deﬁned by the presence of
hematuria (with a dysmorphic glomerular pattern), leuko-
cyturia and presence of cellular casts, is admittedly one of
the most important parameters for characterization of an
active glomerulonephritis. Proteinuria, measured in 24 h or
inferred by the relationship proteinuria/creatininuria (R P/C)
in a random spot urine sample, may also indicate inﬂam-
matory activity.30,31 The positivity or increase in titers of
anti-dsDNA antibodies and low blood levels of complement,
especially with low levels of C3, are also considered as an evi-
dence of renal involvement, but these indicators should not be
used in isolation to deﬁne this condition.30 The reduction in
glomerular ﬁltration, nephrotic proteinuria and the presence
of hypertension (HBP) suggest greater severity and a worse
prognosis.32,33
In patients with APS associated with SLE, the presence of
HBP and renal dysfunction should be considered as an alert
to the possibility of a vasculopathy associated with antiphos-
pholipid antibodies (aPl), especially when there are no signs
of GN detected in urinary sediment.34n microscopy; OM, optical microscopy; LN, lupus nephritis.
In recent years, several new noninvasive urinary biomark-
ers were described, including lidocalin-type prostaglandin
D synthase (l-PGDS), (1)-acid glycoprotein (AAG), transfer-
rin (TF), ceruloplasmin (CP), neutrophil gelatinase-associated
lipocalin (NGAL) and monocyte chemotactic protein 1 (MCP-
1).35 The combination of these biomarkers with laboratory
parameters of renal function is promising to histologic class
inference and to quantify activity and chronicity (B).35 The
anti-ribosomal P antibody, in the absence of anti-dsDNA, has
also been described as possibly associated with membranous
nephritis in SLE patients, and with a predictive value of better
renal prognosis (B).36,37
The determination of histological class based only on clin-
ical and laboratory parameters is limited. However, the sum of
some elements may suggest one or another particular class – a
necessary inference in daily clinical practice. Patients exhibit-
ing an elevated creatinine (with no other apparent cause),
associated with proteinuria >0.5 g/24 h or R P/C >0.5 and recent
HBP and/or an active urinary sediment (dysmorphic hema-
turia and/or cellular casts), and hypertension, particularly if
accompanied by low blood levels of complement and anti-
dsDNA, probably present PGN (class III or IV). On the other
hand, it is more  likely that patients with proteinuria >2 g/24 h
or R P/C >2, with no urinary sediment activity or hypertension,
especially without anti-dsDNA and with normal complement
levels, are suffering from membranous GN (class V). However,
we cannot exclude an early-stage proliferative lesion, or even
its association, in these patients. In exclusively mesangial
lesions (Class I or II), proteinuria is generally <1 g/24 h or R P/C
<1, serum creatinine levels are normal and patients usually are
not hypertensive. However, in patients with these changes, we
cannot exclude the possibility of early-phase proliferative or
membranous GN. Except in these typical forms, class infer-
ences have very little accuracy, and this is also valid for the
possibility of class overlapping (Table 2).
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Table 2 – SBR recommendations for lupus nephritis management.
Recommendations Agreement
Indications for renal biopsy
Perform a renal biopsy whenever possible and when indicated. a) 1.0
Elevation of serum creatinine with no apparent cause and potentially associated with SLE. a) 1.0
Isolated proteinuria >1.0 g/24 h (or R P/C >1.0). a) 1.0
Proteinuria ≥ 0.5 g/24 h associated with glomerular dysmorphic hematuria and/or cellular casts. a) 1.0
Note: changes must be conﬁrmed with a second test. a) 1.0
Inference of histological class
Possibility to make some inference based on clinical and laboratory criteria. a) 0.54; b) 0.46
Creatinine elevation (with no other cause) associated with proteinuria >0.5 g/24 h or R P/C >0.5 and recent HBP
and/or active urinary sediment: consider as proliferative GN (class III or IV), especially if accompanied by low
blood levels of complement and anti-ds-DNA AB.
a)  0.9; b) 0.1
Proteinuria >2 g/h or R P/C >2, with no activity in urinary sediment or hypertension, and mostly without
anti-ds-DNA AB and normal complement levels, suggestive of membranous GN (class V). However, we cannot
exclude proliferative lesion.
a)  0.9; b) 0.1
Proteinuria <1 g/24 h or R P/C <1 with normal creatinine and without HBP suggests mesangial GN (class II).
However, we cannot exclude initial-stage proliferative or membranous GN.
a)  1.0
Also consider the possibility of other causes of renal injury at all stages of evolution of LN (APSN, renal vein
thrombosis, TIN, ATN, diabetic nephropathy, hypertensive nephropathy and/or nephropathy secondary to
infection).
Care for immunosuppressed patients
Vaccine update. a) 1.0
Avoid live virus vaccines. a) 1.0
Tuberculosis (latent or disease) screening. a) 1.0
Continuous evaluation for infections throughout the period of immunosuppression. a) 1.0
Share risks and beneﬁts of treatment with patient and his/her family. a) 1.0
Guidance on contraception (avoiding estrogens), and risks of pregnancy during treatment. a) 1.0
Empirical antiparasitic treatment. a) 1.0
Consider prophylaxis for Pneumocystis jirovecii in cases of previous infection or in patients with lymphopenia
<500 mm3.
a)  1.0
Prescribe hydroxychloroquine for patients, unless contraindicated. a) 1.0
Obtain an informed and free consent form (IFCF). a) 1.0
Response criteria
The treatment efﬁcacy evaluation should be made with objective criteria of response. a) 1.0
Complete remission: proteinuria <0.5 g/24 h or R P/C <0.5 and normal GFR; or reduction ≤10% of previous value
for the patient or ULN of method (if the ﬁrst is not available) and a normal urinalysis.
a)  1.0
Partial remission: reduction >50% of initial proteinuria with a value <3.0 g/24 h or R P/C <3.0, normal GFR or
reduction ≤10% of the previous value of the patient, or ULN of method (if the ﬁrst is not available) and a
normal urinalysis.
a)  0.9; b) 0.1
Agreement: the numbers in each recommendation express the percentages of agreement among the members, according to the classiﬁcation
used.
AB, antibody; GN, glomerulonephritis; HBP, systemic arterial hypertension; ULN, upper limit of normal; APSN, nephropathy of antiphospholipid
syndrome; ATN, acute tubular necrosis; TIN, tubulointerstitial nephritis; R P/C, ratio proteinuria/creatininuria in a random urine sample; GFR,
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For the purpose of analyzing the response to treatment,
e established criteria that are similar to those adopted by
ULAR21 and ACR.38 Complete remission (CR) was deﬁned as
 proteinuria <0.5 g/24 h or R P/C <0.5, and normal or reduced
FR <10% of the previous value of the patient or of the upper
imit of normal (ULN) for the method (if the ﬁrst option is not
vailable) and a normal urinalysis. Partial remission (PR) was
eﬁned as a reduction of >50% of the initial proteinuria, with
 value <3.0 g/24 h or R P/C <3.0, and a normal GFR or a reduc-
ion of <10% of the previous value or of ULN for the method
if the ﬁrst option is not available) and a normal urinalysis
Table 2).Care  for  immunosuppressed  patients
The immunosuppression caused by disease and/or its
treatment increases the risk of infection, including the
opportunistics,39 and often the differential diagnosis with
disease activity is a challenging task in clinical practice.40
Infections are associated with increased morbidity and mor-
tality in SLE2,3 and, therefore, prevention strategies, such as
vaccination, use of antimicrobials and antiparasitic drugs,
preferably before the start of immunosuppressive therapy,
should be implemented. Moreover, tuberculosis can also be a
factor of disease activation.41 Risk factors for major infections
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are: leukopenia/lymphopenia, low blood levels of comple-
ment, hypogammaglobulinemia, splenectomy, and the use of
CS and immunosuppressants,42 usual conditions during the
whole treatment of LN, so that a continuous assessment must
be made for the presence of infection throughout the period
of immunosuppression.
On the other hand, it was demonstrated that the use
of hydroxychloroquine (HCLQ) is associated with a lower
frequency of infections in patients with SLE.43 Due to the mor-
bidity and mortality related to infections, the sharing of risks
and beneﬁts of treatment with the patient and his/her family
is strongly sugested, as well as providing speciﬁc clariﬁcation
on the medications used, including signing of an Informed
Consent Form.
All patients should also be counseled about contraception
and pregnancy risks during treatment (Table 2).
Vaccination
An update of the vaccination card should always be per-
formed, preferably with the disease in an inactive period
and before the implementation of any synthetic or biologi-
cal immunosuppressive therapy.44,45 Vaccines without living
organism – (inﬂuenza IM); pneumococcal; tetanus; diphthe-
ria; pertussis; Haemophilus type B; viral hepatitis A and B,
poliomyelitis (inactivated – IPV); meningococcal; HPV; typhoid
fever (IM); and rabies – are safe at any stage of treatment and
often determine an adequate immunogenicity.46,47 In this con-
text, the most important vaccines are:
a) Pneumococcal (23-valent polysaccharide): must be admin-
istered every ﬁve years48 as recommended by the Programa
Nacional de Imunizac¸ões (PNI) (National Immunization
Program) of Brazil. However, the Sociedade Brasileira de
Imunizac¸ão (SBIM) (Brazilian Society of Immunization) in
agreement with the Centers for Disease Control of the
United States, has recommended that the vaccine used in
immunosuppressed individuals must be the pneumococ-
cal conjugate vaccine, followed by polysaccharide vaccine
after 8 weeks (CDC, 2011);
b) Inﬂuenza: the vaccine must be administered annually49;
(c) Diphtheria and tetanus (dT): follow PNI guidelines.
The live virus vaccines (MMR,  herpes zoster and yellow
fever) should be avoided and used only in special cases, after
a joint evaluation with an infectologist (Table 2).42
Antimicrobial  prophylaxis
a) Tuberculosis: the treatment of latent tuberculosis, espe-
cially in the case of positive epidemiological data, should
be considered in cases with tuberculin test – PPD ≥5 mm
(if the patient is using CS) or with a chest radiograph sug-
50gestive of prior untreated tuberculosis.
b) Pneumocystis jirovecii: indication of prophylaxis before the
onset of immunosuppression in cases of previous infec-
tion by this organism and in patients with lymphopenia. 2 0 1 5;5 5(1):1–21
<500 mm3, especially if associated with a genetic or
acquired hypocomplementemia.51
(c) Antiparasitic agents: before immunosuppression, an
empiric treatment with broad spectrum anthelmintics
(e.g., albendazole or ivermectin) is recommended, espe-
cially in patients with positive epidemiological data – an
almost universal condition in our country (Table 2).
Mesangial  glomerulonephritis  (classes  I  and  II)
–  induction  and  maintenance  therapy
For most patients with mesangial GN, the treatment is offered
only with CS and HCLQ. However, for those patients who
experience persistent proteinuria >1.0 g/24 h (or R P/C >1.0),
one must consider the combination of azathioprine (AZA) or
mycophenolate mofetil (MMF) (Table 3).
Proliferative  glomerulonephritis  –  remission
induction  therapy
Better-quality randomized controlled studies evaluating dif-
ferent treatment regimens in LN had as inclusion criteria the
conﬁrmation and classiﬁcation of nephritis according to renal
biopsy. This approach has the advantage of avoiding an aggres-
sive treatment for mild cases, with no indicative factors of
severity, as well as the implementation of ineffective treat-
ments in patients with chronic and irreversible changes. It is
recognized that the treatment is urgent and it must be inten-
sive in proliferative forms of LN (classes III and IV, with or
without association with class V), in which the risk of pro-
gression to renal failure is high.21 The target to be achieved in
six months (induction period) is CR.
Since studies published in the 80s, the superiority of
cyclophosphamide (CY) has been acknowledged, as compared
to the isolated use of CS in the treatment of PGN.52 The use of
CY for prolonged periods was more  effective for the preven-
tion of relapse and for maintaining renal function53; however,
this drug is associated with multiple side effects, particularly
gonadal insufﬁciency.54
In a controlled, randomized, multicentre study on LN (class
III/IV and V[16%]), the effectiveness of MMF  was not inferior
to intravenous (IV) CY in a conventional scheme,55 conﬁrming
earlier studies.56,57 Meta-analyses also showed that CY and
MMF have comparable efﬁcacy (A).58–60
Cyclophosphamide may be used in low doses (Scheme Euro
Lupus Trial – ET), consisting of the administration of 500 mg
IV every 2 weeks for 3 months (total dose of 3 g), followed by
maintenance with AZA61; or at high doses (classical scheme –
“NIH”) of 0.5–1.0 g/m2 of body surface area (BSA) IV at monthly
intervals for 6 months, followed by applications at quarterly
intervals for another 18 months.52 In a study comparing high-
dose (for 12 months) versus low dose (for three months) of CY,
both followed by AZA, the authors observed after 10 years
no difference in the doubling of creatinine value, evolution
7to ERF and mortality. It should be emphasized that these
results were obtained in studies with European patients,
whose severity of nephritis tends to be lower than that
observed in African descendants.10,61 A systematic review
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Table 3 – SBR recommendations for the treatment of lupus nephritis including proliferative and mesangial types.
Recommendations Agreement
Adjuvant measures for all histologic classes
The use of hydroxychloroquine (preferably) or chloroquine is recommended for all patients (unless
contraindicated) during induction and maintenance phases.
a)  1.0
ACE inhibitors and/or ARBs are recommended as antiproteinuric agents for all patients (unless
contraindicated).
a)  1.0
Prevent and treat risk factors for cardiovascular disease: physical inactivity, dyslipidemia (LDL <100 mg/dL),
diabetes, obesity, HBP (BP <130 × 80 mmHg) and smoking.
a)  1.0
Encourage a diet rich in calcium and consider supplementation, when necessary. a) 1.0
Consider supplementation of vitamin D (25 (OH) (if vitamin D serum levels >30 ng/mL). a) 1.0
Avoid nephrotoxic drugs, especially non-steroidal anti-inﬂammatory agents. a)  1.0
Protocol for induction and maintenance in mesangial GN (classes I and II)
For patients with persistent proteinuria ≥1.0 g/24 h or R P/C ≥1.0: induction and maintenance of remission,
consider AZA or MMF.
a)  1.0
Protocol for induction in proliferative GN (classes III and IV)
Target to be achieved in six months is RC. a) 1.0
The identiﬁcation of clinical and/or laboratory signs suggestive of proliferative GN should indicate an
immediate speciﬁc therapy, including CS and an immunosuppressant agent, even in cases when histological
conﬁrmation is not possible.
a)  1.0
The treatment should begin with MP pulse therapy [0.5–1.0 g IV (or 10–30 mg/kg/day in PSLE patients) for 3
days]. Doses of prednisone between 0.5 and 1.0 mg/kg/day for 3–4 weeks, with subsequent reduction and with
the goal of achieving a dose of 5–10 mg/day for 6 months.
a)  0.9; b) 0.1
In conjunction with CS, include CY IV 0.5–1.0 g/m2 BSA monthly for 6 months, or CY IV 0.5 g every 15 days for 3
months, or MMF (2–3 g/day).
a)  0.9; b) 0.1
In patients with severity criteria, consider CY as a ﬁrst option, taking into account its availability, absorption
and tolerance to medication and treatment adherence.
a)  0.9; b) 0.1
Lack of response or worsening of renal disease after 3 months of an appropriate therapy suggests the need to
consider an early change of the induction protocol.
a)  1.0
After 6 months of treatment at this stage, if CR or PR were not achieved, the patient should be considered as
refractory to induction; in this case, a new therapy with MP and replacement of CY by MMF, or of MMF by CY,
are recommended.
a)  1.0
Protocol for maintaining proliferative GN (classes III and IV)
AZA or MMF are indicated for patients who have achieved CR or PR in the induction phase. a) 1.0
These medications must be used for at least 36 months, but they can be kept for longer periods. Their
suspension should only be performed after achieving and maintaining a complete and continuous remission.
a)  1.0
The doses of corticosteroids should be reduced progressively and, if possible, discontinued, ideally after
achieving and maintaining a complete and sustained remission.
a)  0.9; b) 0.1
Agreement: the numbers in each recommendation express the percentages of agreement among the members, according to the classiﬁcation
used.
AZA, azathioprine; ARB, angiotensin receptor blockers; ACEI, angiotensin-converting enzyme inhibitors; CY, cyclophosphamide; CS, cortico-
steroids; GN, glomerulonephritis; HBP, systemic arterial hypertension; MMF, mycophenolate mofetil; MP, methylprednisolone; CR, complete
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f ten randomized controlled trials found that low doses of
Y, when compared to higher doses, had similar efﬁcacy in
educing relapses, but with lower infection rates (A).62
The use of CY PO was evaluated retrospectively in a
eries of patients with LN (class III, IV and V). The dose of
.0–1.5 mg/kg/day for an average use of 4 months was effective
n controlling LN, with frequency of side effects and the need
or discontinuation of the medicament occurring in less than
0% of the patients, without difference in response between
uro- and African descendants.63 Previous studies have shown
fﬁcacy of CY PO in Chinese patients, comparable to CY IV
64.65C).
In a subgroup exploratory analysis of ALMS study, it was
bserved that although CY and MMF  IV have presented similar
fﬁcacy, race, ethnicity, and geographic region factors seem to a random urine sample; BSA, body surface area; GFR, glomerular
have inﬂuenced the response to treatment of LN. Groups of
African American and Hispanic patients appear to have had
a better response to MMF versus CY, and Asian patients had
more side effects to MMF. But, as this was a subgroup analysis,
these results cannot be considered conclusive (C).66
In another post hoc analysis evaluating only 32 patients with
severe renal impairment (creatinine clearance <30 mL/min) it
was observed that the reduction of proteinuria and serum cre-
atinine was comparable in patients using MMF  and CY, with
no signiﬁcant difference in the frequency of side effects (C).67
There is only one randomized controlled trial speciﬁcally
designed to include cases of severe NL (GFR 25–80 mL/min
or with crescent cells/necrosis in more  than 25% of the
glomeruli), in which high doses of CY IV associated with
pulsed methylprednisolone (MP) were effective (C).68 Thus,
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there are virtually no studies designed to evaluate the efﬁ-
cacy of MMF  in these patients with severely impaired renal
function.
The use of AZA as induction therapy in PGN is not recom-
mended, because studies showed less effectiveness versus CY
in this phase of treatment.52,69 One study with repeated renal
biopsy also showed that AZA was less effective in preventing
the evolution to glomerular ﬁbrosis.69 However, AZA may be
a therapeutic option in LN for Euro-descendants without pre-
dictors of severity and who  do not tolerate CY or MMF,  despite
the higher risk of nephritis reactivation when comparing this
agent to CY (C).69
In women with LN who still wish to become pregnant, it
is recommended preferably the use of MMF,  as CY is associ-
ated with an increased risk of infertility, particularly in those
women over 30 years and that had a prolonged use of this
agent (approximate risk: 60%). However, MMF  is formally con-
traindicated during pregnancy because its teratogenicity; and
it must be emphasized the need for an effective contraception
during its use. The use of CY for shorter periods (6 months) in
young women, even at high doses, is associated with lower
rates of infertility (4.3–10%),7,54 a percentage similar to the
Eurotrial scheme (4.5%).7 Given the greater number of side
effects with MMF  use in Asians, doses ≤2 g/day are recom-
mended in these patients. Given that some studies showed
a worse response of CY in African-descendant and Hispanic
patients, it may be advantageous the use of MMF in these
cases. However, we  should point out that a study speciﬁcally
targeted to the Brazilian population with the use of this agent
has not yet been published (Table 3).
Corticosteroids
Although in most studies CS were administered PO at doses
of 0.5–1 mg/kg/day with gradual reduction, pulse therapy IV
with MP  for three days at the beginning of treatment could
allow the subsequent use of lower doses of CS PO, as shown
by Houssiau.70 In order to reduce the side effects of high doses
of CS, and also to allow a more  rapid control of the inﬂam-
matory process, the use of MP  at a dose of 0.5–1.0 g/day IV
(or 10–30 mg/kg/day for pediatric patients) for 3 days is rec-
ommended, keeping the prednisone dose in 0.5–1.0 mg/kg/day
for 3–4 weeks, followed by a progressive reduction, aiming to
achieve doses of 5–10 mg/day after six months. Some extra-
renal manifestations may require maintaining higher doses
for longer periods, but due to the high frequency of adverse
effects of CS, every effort should be made for reducing the daily
dose. Patients with worse prognosis factors, e.g., presence of
cellular crescents and of necrosis, as well as those with higher
creatinine levels, should receive higher doses of prednisone
(1.0 mg/kg/day).20
In the case of achieving only PR after 6 months of an appro-
priate treatment, the induction phase may be extended from
7 to 9 months, according to clinical judgment.
After six months of induction treatment, if CR or PR
has not been achieved, the patient is considered with
refractory LN and a new induction therapy with MP and
replacement of CY by MMF  or MMF  by CY is recommended
(Table 3).. 2 0 1 5;5 5(1):1–21
Proliferative  glomerulonephritis  –  maintenance
treatment
Although there is no evidence to establish the duration of
the induction phase, most authors and international consen-
suses consider the period of six months.20,71 At the same time,
changing the therapeutic regimen for that of maintenance
phase depends on CR or PR achievement. In some instances,
even after the ﬁrst six months of induction, a second scheme
will be required until CR or PR is reached. Controlled stud-
ies that have addressed the duration of this phase are also
lacking, but most authors agree that it should last 24–48
months. For patients with PGN, there are two  major acknowl-
edged alternatives for patient maintenance: AZA or MMF,
both associated with low-dose prednisone (5–10 mg/day). The
maintenance with CY IV every 3–4 months has not been used
anymore, due to its side effects and also because the available
options (AZA or MMF) have proven reasonably safe, with few
side effects in the long term.
These two immunosuppressive agents were compared in
two studies, MAINTAIN72 and Aspreva Lupus Management
Study – ALMS.71 The designs of these studies were different
and did not show the same outcomes. The MAINTAIN study
included European Caucasian patients and did not show sig-
niﬁcant differences between drugs. On the other hand, the
ALMS study, which selected only patients who had achieved
good responses in the induction phase with CY IV or MMF  for
six months and that occurred in little more  than 50% of those
patients included, showed superiority of MMF  versus AZA in
preventing new episodes of renal activity.
EULAR recommends that patients with good responses to
induction therapy for LN should use MMF  (2 g/day) or AZA
(2 mg/kg/day) for at least three years, while other authors rec-
ommend at least ﬁve years, with discontinuation of the drug in
a very gradual manner and under monitoring.73,74 The discon-
tinuation of this medication should be gradual and initiated
always by CS.21
ACR also recommends that patients who  responded to
induction therapy have a maintenance treatment with AZA
2 mg/kg/day or MMF 2 g/day, combined with low doses of CS.
According to ACR, the existing data are insufﬁcient to rec-
ommend the time to dose reduction or discontinuation of
medication (A).20
In summary, in the maintenance therapy of patients with
PGN with complete or partial response in the induction phase,
they should be treated with AZA or MMF,  and the choice should
be evaluated case by case. Mycophenolate sodium may also be
an option to mycophenolate mofetil, if there is intolerance to
this latter drug.
Facing the possibility of pregnancy, it is preferable to
administer AZA, considering the teratogenicity of MMF.  Due  to
the high cost of MMF and the favorable results for those milder
forms of LN, patients without markers of severity of LN and
who have had a complete response can be treated with AZA
as ﬁrst choice in their maintenance phase.
Results of some studies and, especially, the opinion of
some authors suggest that AZA could be administered prefer-
ably in Euro-descendants,75 and MMF  in African descendants
(Table 3).66
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embranous  glomerulonephritis  –  induction
reatment
embranous GN (MGN) is present in 10–20% of cases under-
oing biopsy. This disease can occur alone or in association
ith other histological classes.76 The usual expression of MGN
s the presence of proteinuria and edema without concomi-
ant systemic manifestations, complement consumption or
resence of anti-ds-DNA (D).77 the classic features of GN, as
ematuria (dysmorphic), cellular casts, HBP and early ele-
ation of serum creatinine, are infrequent. As with other
lasses, MGN  can also progress from a “silent” type, including
 slightly elevated proteinuria.78 On the other hand, nephrotic
yndrome (NS) occurs in up to 75% of patients,79 represent-
ng a greater risk of venous thrombosis (3–22%), including
enal veins (a still greater risk in patients with aPl),80,81 coro-
ary artery disease (RR = 2.8) and acute myocardial infarction
RR = 5.5).82 The association of MGN  with proliferative forms
etermines a worse prognosis and, even in isolated forms,
–53% of patients progress to ERF in 10 years (C).80,82 Thus,
t is understood that despite MGN  not being the most aggres-
ive histological class in LN patients, we should not consider
t as a mild form of renal involvement.
Nonetheless, there are few studies available in the lit-
rature, and most of them evaluating small series, with
hort periods of observation and varied treatment regi-
ens with respect to doses of CS, concomitant use of MP,
se of angiotensin-converting enzyme inhibitors (ACEI) or
ngiotensin receptor blockers (ARBs) and especially with het-
rogeneity of response criteria (reduction in proteinuria versus
R/PR rates).
AZA is one of the more  often used immunosuppressants
n the treatment of SLE patients and, by having a better safety
roﬁle than other agents, this drug has been long used as a
S-sparing agent and even in the treatment of milder GNs.
owever, few prospective studies with this drug were pub-
ished. In an open-label, prospective, multicenter study with
8 Asian patients on AZA associated with prednisone (without
ulse therapy with MP, or ACE inhibitors or ARBs), the results
ere analyzed at 12 months with respect to CR (whose crite-
ion was: stable or improved serum creatinine and proteinuria
1.0 g/24 h) or PR (reduction in proteinuria of at least 50% with
ub-nephrotic level) rates. CR was achieved in 67% and PR in
2% of patients (refractoriness in 11%). The authors concluded
hat the results with AZA were similar to, or better than, those
btained with other regimens.83
Evidence of response to cyclosporine (CsA) was obtained
n a few studies, each with a small number of patients. One
pen-label study followed 10 patients treated with CsA asso-
iated with prednisone for 24 months. The only response
riterion was the intensity of proteinuria decrease, but in
ome patients, an increase in creatinine, secondary to this
gent, was observed. Thus, CsA does not seem to be a suit-
ble option, except for refractory cases, with its use as an
lternative therapy.84In some studies, CY has been used for induction in cases
f MGN.  One of these studies prospectively followed 20
atients with MGN  and NS; the induction was done with
ral CY (2.0–2.5 mg/kg/day) for 6 months in combination with2 0 1 5;5  5(1):1–21 9
prednisone, with sequential reduction and maintenance
with AZA (without adjuvant therapy with ACEI and/or ARB
or pulse therapy with MP). The response was based on the
achievement of CR (proteinuria <0.3 g/24 h, stable serum
creatinine and a normal urinalysis) or PR (proteinuria >0.3
and <3.0 g/day, a stable creatinine). In 12 months, CR and PR
were achieved in 55% and 35% of patients, respectively.79
Cyclophosphamide was also evaluated in a randomized
controlled study comparing this drug with CsA and with
prednisone alone for induction of remission in GNM patients
with NS. CY IV was administered every two months for one
year (0.5–1.0 g/m2 BSA) and CsA daily (5 mg/kg/day) for 11
months; both medications were associated with prednisone
and ACE inhibitors, as decided by the assistant physician. CR
and PR rates obtained in 12 months with CY were 40% and
20%, respectively, compared with 50% for CR and 30% for PR
obtained for CsA and 13% for CR and 23% for PR with pred-
nisone alone. Both immunosuppressants were superior to CS
used alone (p = 0.002); however, throughout the observation
period (12 months), there were more  relapses with CsA versus
CY (p = 0.02) (B).85
MMF  was used for induction of remission in GNM, although
in a few studies with a small number of cases, most of them
with no more  than 20 patients. In 2010, a study gathered data
from two multicentric randomized controlled trials, with sim-
ilar protocols previously published which evaluated responses
of the induction of remission in 6 months with regimens
including CY or MMF  in patients suffering only MGN  (n = 84).
Patients were treated with CY IV (0.5–1.0 g/m2 BSA monthly);
MMF  was administered at a dose of 2–3 g/day, both for 6
months. No pulse therapy with MP was used. The majority
of patients were treated with ACE inhibitors. There was no
difference between groups regarding the percentage change
in proteinuria and serum creatinine, and CR was achieved by
only 1 (2.5%) patient, while PR was achieved by 60% of patients
in both groups. The analysis was limited to patients who com-
pleted treatment (analysis per protocol); furthermore, 23% of
cases were lost to follow up during the observation period after
six months (induction); nevertheless, the authors assumed
that the induction treatment for GNM with MMF  have been as
effective as with CY,86 although in both groups (CY and MMF)
the rates of complete/partial remission were low (B).
MMF  was also used for induction of remission in patients
with MGN as compared to tacrolimus (TAC). Yap et al. stud-
ied 16 patients with GNM and NS whose treatment was done
with MMF (7 cases) or TAC (9 cases), both associated with
prednisone, whose initial dose was 0.8 mg/kg/day (without
association of ACEI or ARB). In both groups an improvement
in proteinuria was observed, but remission rates were only
determined at 24 months (CR for MMF  and TAC, 57% and 11%,
respectively, and PR for MMF  and TAC, 11% and 44%, respec-
tively). The authors demonstrated that the time to reach a
(complete) response to treatment was 15.3 months for MMF
and 21.7 months for TAC.6
It is also likely that, in cases of MGN, the concomitant
use of hydroxychloroquine (HCLQ) during induction treatment
is valid, as suggested by evaluation data from a prospec-
tive cohort that included 29 patients with a recent diagnosis
of this histologic class (34.5%) or in combination with PGN
(65.5%). Immunosuppressive treatment was done with MMF;
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Table 4 – SBR recommendations for the treatment of membranous nephritis.
Recommendations Agreement
Protocol for induction in membranous GN (class V)
CR or PR are the targets to be achieved in six months. a) 1.0
Immunosuppressants are recommended for all patients, because they are more effective than CS as
monotherapy.
a)  1.0
Attention should be given to the exclusion of thromboses, including into renal veins, which are frequently
present with positivity for aPl.
a)  1.0
The treatment should begin with MP pulse therapy [0.5–1.0 g IV (or 10–30 mg/kg/day in PSLE patients) for 3
days] followed by prednisone (0.5–1.0 mg/kg/day) for 3–4 weeks, with subsequent reduction and with the goal
to achieve a dose of 5–10 mg/day within six months.
a)  1.0
In conjunction with CS, CY IV 0.5–1.0 g/m2 BSA monthly for 6 months, or CY IV 0.5 g every 15 days for 3
months, or MMF (2–3 g/day) and AZA (2 mg/day) should be included.
a)  0.9; b) 0.1
Lack of response after 3 months of an appropriate therapy indicates the need to consider an early change of
induction protocol.
a)  0.9; b) 0.1
After 6 months of induction treatment, if CR or PR have not been achieved, LN is considered refractory, and a
new induction therapy with MP and an exchange of the immunosuppressive agent (CY, MMF or AZA) are
recommended.
a)  1.0
Protocol for maintenance in membranous GN (class V)
The modiﬁcation of the treatment regimen for that of the maintenance phase depends on achieving CR or PR. a) 1.0
AZA or MMF are indicated for patients who have achieved CR or PR in the induction phase. a) 1.0
For patients who have not achieved a favorable response with AZA or MMF, switching to one another, or the
substitution by a calcineurin inhibitor or rituximab, should be considered.
a)  1.0
These medications must be used for at least 36 months, but they can be kept for longer periods. Their
suspension should only be performed after achieving and maintaining a complete and continuous remission.
a)  1.0
The doses of corticosteroids should be reduced progressively and, if possible, discontinued, ideally after
achieving and maintaining a complete and sustained remission.
a)  0.9; b) 0.1
Agreement: the numbers in each recommendation express the percentages of agreement among the members, according to the classiﬁcation
used.
aPl, antiphospholipid antibodies; AZA, azathioprine; CY, cyclophosphamide; CS, corticosteroids; GN, glomerulonephritis; MMF, mycophenolate
mofetil; MP, methylprednisolone; LN, lupus nephritis; CR, complete remission; PR, partial remission; BSA, body surface area.and among the 11 patients (38%) achieving complete renal
remission in 12 months, seven had been treated with HCLQ
compared with four patients without HCLQ (p = 0.036) (C).87
In summary, we  can admit that, in relation to MGN, there
exists little scientiﬁc evidence to guide our clinical decisions,
but it is likely that we  should not regard them as mild forms
of LN (Table 4).
Membranous  glomerulonephritis  –
maintenance  treatment
Just as in PGN, the maintenance treatment in cases of MGN
also includes an immunosuppressive agent such as AZA or
MMF,  in combination with prednisone at progressively lower
doses. Except for the ALMS study, there are no other ran-
domized controlled trials examining AZA in the maintenance
of remission in patients with MGN.  Nevertheless, this agent
has been widely used in most centers and Mok, in 2009, pub-
lished the results of an open-label study with an observation
period of 12 ± 6 years, in which all patients received induction
with AZA and prednisolone. At the end of this long observa-
tion period, 35% had suffered relapses, and despite the need
for the use of other immunosuppressants and for increasing
doses of CS, 79% of patients had reached proteinuria valueslower than 1.0 g/24 h with preservation of renal function, and
21% had a proteinuria higher than 1.0 g/24 h, although still in
a subnephrotic level. The doubling of serum creatinine was
observed in 8% and no patient progressed to ERF.80 The study
design was not ideal and, furthermore, only included Chinese
patients; however, longer observation period and the favorable
results allow us to admit that AZA has potential for use in the
maintenance period (C).
In the ALMS study,71 which evaluated the maintenance
phase with MMF or AZA, only patients who had achieved a
favorable response in the induction phase were included. Most
patients presented PGN, but about 15% exhibited pure MGN
(18 cases in MMF  group and 17 in AZA group), and for these
patients, there are no speciﬁc response data.
The recommendations of EULAR and ACR suggest the use
of either of the two medications (D).20,21 However, there is no
publication or consensus establishing the maximum time of
therapy, as well as how fast should be the reduction of the
selected medication.
CsA has been evaluated in a randomized controlled study
of induction and maintenance in the short-term (12 months)
and, when compared to the isolated use of prednisone, the
drug was more  effective as regards the achievement of CR
(B).85 However, the period of one year does not allow us to
generalize the long-term response to this agent, especially if
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ne considers the high frequency of relapses during follow-
p.
Some case series suggest the use of TAC, with less nephro-
oxic potential in the patient’s maintenance.73,86 TAC could be
sed in special cases, such as in patients with normal renal
unction, negativity for aPl and persistently elevated protein-
ria (D).
Although the results with CY for the maintenance phase
re not favorable compared with AZA or MMF,  this medication
an also be considered as an alternative of exception for main-
enance in patients with known poor adherence to treatment
D).54,88
Although the existing data in the literature are incon-
istent, we  understand that, for the maintenance phase,
n addition to low doses of prednisone (ideally less than
0 mg/day), the most suitable agents are AZA (2 mg/kg/day) or
MF  (2–3 g/day) in combination with HCLQ and an adjuvant
herapy, as discussed below. In cases of MGN  refractoriness,
ne can consider the use of calcineurin inhibitors, especially
AC and even RTX (Table 4).21
enal  involvement  in  the  antiphospholipid
ntibody  syndrome  –  diagnosis  and  treatment
enal involvement can occur in primary or secondary APS, but
he impact on prognosis in NL patients is still controversial.89
Pl (anti-cardiolipins, anti-2-glycoprotein I and lupus antico-
gulant) may trigger intrarenal vascular lesions, determining
he development of an APS associated nephropathy (APSN).90
The clinical picture is characterized by HBP, non-
ysmorphic hematuria, proteinuria and worsening of renal
unction, which may be acute, with rapid progression to dial-
sis; or chronic, with slow and progressive evolution.34,91–93
cute renal artery thrombosis evolves mainly with an acute,
evere, difﬁcult-to-control hypertension, with or without low
ack pain, hematuria and acute renal failure.90 On the other
and, renal vein thrombosis evolves mainly with proteinuria,
hich can reach nephrotic levels and, if it occurs in a com-
lete and acute form, may be associated with a sudden low
ack pain and loss of renal function.90
Histopathological ﬁndings of APSN occur in 4–40% of
LE patients, being more  frequent in patients with a previ-
us diagnosis of APS.34,89,91–94 Thrombotic microangiopathy
s the most important acute injury; it is characterized by
he presence of ﬁbrin thrombi in glomerular capillaries and
rterioles.95 However, this injury is hardly found alone in
atients with SLE, given the frequent overlapping with the
istopathological changes of lupus nephritis.34 The following
hronic injuries are frequently found, although they have less
peciﬁcity for the diagnosis of APSN: ﬁbrous intimal hyper-
lasia and the presence of organized thrombi with or without
ecanalization, ﬁbrous or ﬁbrocellular occlusion of arteries
nd arterioles, tubular tireoidization characterized by atrophy
f tubules with eosinophilic casts, and focal cortical atro-
hy with or without depression in the contour of the renal
apsule.95 The association of at least one acute or chronic
istopathological ﬁnding with the presence of aPl deﬁnes
PSN.95,96 0 1 5;5 5(1):1–21 11
The main differential diagnoses involve clinical condi-
tions associated with clotting disorder or endothelial injury,
such as thrombotic thrombocytopenic purpura, hemolytic
uremic syndrome, malignant hypertension, diabetes, sclero-
derma renal crisis, pre-eclampsia (PE), drug toxicity (CsA and
chemotherapics) and renal transplant rejection.34,91–96
APSN was associated with lupus anticoagulant, ACL IgG
and beta 2 GPI, and even more  often when two or more  of these
aPl are present. However, during the vasoocclusive event these
antibodies may be temporarily absent.89,94,96
Echography with color Doppler, scintigraphy with 99m
Tc-DMSA and renal-vessel angiography assist in the identi-
ﬁcation of vascular involvement,97 but the histopathological
changes necessary for the diagnosis of APSN are identiﬁed by
renal biopsy.90
All patients with SLE and aPl must control the risk factors
for thrombosis: obesity, HBP, smoking, diabetes and dys-
lipidemia. Furthermore, these patients should avoid using
estrogen contraceptives and hormone replacement therapy
(D).98 In cases of venous thrombosis, anticoagulation is indi-
cated indeﬁnitely with an INR between 2.0 and 3.0 (B).99 In
cases of arterial thrombosis, although with this same rec-
ommendation, some authors advocate the combination of
anticoagulation with an antiplatelet agent or maintaining an
INR above 3.0 in recurrent cases (C).98 The use of statins could
also play an adjuvant role in the treatment of patients with
APS (C)98 and in patients with APSN, one should take into
account the use of HCLQ and an antiplatelet agent, or anti-
coagulation (B).21,100
Adjuvant  therapy  in  lupus  nephritis
In addition to the judicious use of immunosuppressive agents,
both in induction of remission as in the maintenance phase,
several other measures can also contribute positively, not only
to obtain a better control of the inﬂammatory process, but also
for the preservation of renal function in the long term. These
measures consist of non-pharmacological and pharmacolog-
ical recommendations listed below:
(a) Provide dietary counseling for the prevention and control
of dyslipidemia, diabetes, obesity, HBP and osteoporosis.
Encourage a balanced diet with proteins, lipids and carbo-
hydrates, with low levels of salt (D).101
(b) Consider vitamin D supplementation for all patients, with
doses 800–4000 IU/day, with sequential adjustments; the
serum levels of 25 (OH) vitamin D should remain above
30 ng/mL, although the clinical beneﬁts are still negligi-
ble (B).102,103 Encourage a calcium-rich diet and consider
its supplementation in cases where there is a need, espe-
cially in patients treated with CS and in postmenopausal
women (C).101
(c) Avoid the use of nephrotoxic drugs, particularly nons-
teroid anti-inﬂammatory drugs (NSAIDs) (C).104
(d) Strongly encourage smoking cessation (C).101(e) Establish a strict control of blood pressure, targeting lev-
els at or below 130/80 mmHg, in which there is a greater
chance of preservation of renal function (A).105 There is a
preference for the use of ACEI or ARB, whose efﬁcacies
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are already well established for chronic kidney disease
from other etiologies, (a)106 and by their renoprotec-
tor and antiproteinuric effects. For that reason, these
agents should be used even in patients with normal blood
pressure levels. These drugs should be used with cau-
tion in cases of renal failure, since they can both cause
hyperkalemia, but can also reduce the ﬁltration pressure,
with a subsequent decline in glomerular ﬁltration rates
(A).107–110 The association of these classes of antihyperten-
sive drugs appears to have an even greater antiproteinuric
effect; however, their impact on renal function in the
long term has not yet deﬁned.110 The dose should be
adequate for a maximum antihypertensive and antipro-
teinuric effect, with monitoring of potassium levels and
renal function.21
(f) HCLQ is associated with higher rates of response to
treatment, lower frequency of relapses, less severe kid-
ney damage, reduction of thromboembolic events and
increased survival; for all that, this medication is indi-
cated for all patients with LN, both in their induction
and in maintenance phases, unless contraindicated
(B).20,21,87,111–114 An ophthalmologic evaluation should be
performed before starting the treatment and should be
repeated annually after ﬁve years of continuous use,
except in cases with increased risk for development of reti-
nal toxicity: elderly patients; renal or hepatic dysfunction;
HCLQ >400 mg/day (>6.5 mg/kg/day); cumulative dose of
HCLQ >1000 g; or presence of prior retinal disease or mac-
ulopathy. In these cases, it is recommended an interval of
one year after starting the treatment with HCLQ.115
(g) Contraceptives containing estrogens should be avoided,
especially during the active phase of the disease, or if
the patient has a prior history of cardiovascular event
or of increased risk of occurrence of thromboembolic
events (B).116 The use of hormone replacement therapy
also should be avoided (B).117
(h) The treatment of dyslipidemia with statins should
be recommended for patients with LDL cholesterol
>100 mg/dL,20 despite the small number of studies involv-
ing patients with SLE (C).118,119
Refractory  lupus  nephritis
Despite the signiﬁcant improvement in survival and in the
preservation of renal function in most patients with LN,
about 10–29% progress to ERF.16,120 This progression can occur
silently,78 or may be evident through the evolution, being more
common in patients who develop proliferative forms. In most
studies, at the end of the induction period, less than 50% of
the individuals achieve CR74; in clinical practice, a more  real-
istic goal seems to be the achievement of PR or CR in a period
from 6 to 12 months. Cases that do not achieve CR or PR after
this time with an appropriate treatment could be classiﬁed as
refractory to the regimen instituted.
There are various clinical and/or laboratory aspects related
to refractoriness, and among these, the most common are:
LN appearance in adolescence, male gender, low blood levels
of complement, thrombocytopenia, elevated serum creatinine
and massive proteinuria at diagnosis of LN.11,121 Some factors. 2 0 1 5;5 5(1):1–21
are directly related to the aggressiveness of glomerular inﬂam-
matory events, such as new episodes of renal reactivation,
particularly in the ﬁrst 18 months of the disease, massive pres-
ence of crescents and/or vascular necrosis, histological trans-
formation, or overlapping of lesions secondary to APS.122–128
On the other hand, the refractoriness to LN may be related to
other variables, such as delaying the start of an effective treat-
ment, besides an impossibility of compliance with the treat-
ment protocol, either by infection and/or temporary suspen-
sion of medicines, or by poor adherence to treatment.29,129–131
Patients with treatment-refractory lupus nephritis (RLN)
should be further evaluated for the presence of other pos-
sible causes of persistent proteinuria or renal function loss,
for example, use of nephrotoxic drugs, thrombosis of renal
veins/arteries, infections, and decompensated hypertension
or diabetes mellitus.20,21,29 Another condition that deserves
to be investigated is the overlapping of injury secondary to
tubulointerstitial nephritis (TIN) related, in most cases, to
the use of antimicrobial agents, too common in phases of
increased immunosuppression. The most suggestive ﬁndings
are hyperuricemia, hypokalemia, isosthenuria and renal tubu-
lar acidosis, as well as ﬁndings in the urinary sediment, which
may be the presence of a greater quantity of kidney tubule cells
in association with absence of ﬁndings indicative of active GN.
In isolated cases, other causes of proteinuria (glomerulopa-
thy secondary to diabetes, syphilis, or to HIV or HCV infection)
can also co-exist, or may arise during the evolution, giving the
impression of refractoriness. In the case of RLN, a new renal
biopsy may be indicated, because this procedure may allow
the identiﬁcation of lesions (like some of those above) or the
characterization of the presence of exclusively chronic lesions
– or characterization of the presence of pure chronic lesions –
and in the latter case, further immunosuppression would not
beneﬁt the patient (A).131,132
After identifying a non-treatment responsive, persistent
inﬂammatory activity, RTX, an anti-CD20 monoclonal anti-
body, has been considered as therapeutic option. Published
studies of case series involving patients classiﬁed as refrac-
tory to treatment have shown good response in 47–89% of
cases.132,133 In a prospective controlled trial with RTX (LUNAR),
which included patients with LN, no superiority of RTX was
demonstrated, when this drug was used in combination with
MMF and CS versus placebo. But it is likely that these nega-
tive results were more  due to the study design than the lack
of efﬁcacy of the drug.134 Despite the lack of controlled stud-
ies demonstrating efﬁcacy of RTX for treatment of LN, this
drug has been used with good results in most reference cen-
ters, and currently its use is recommended in the consensuses
of EULAR and ACR for patients considered refractory, both in
cases of PGN and MGN.20,21 The administration regimen and
doses used are similar to the recommendations for rheuma-
toid arthritis (two doses of 1000 mg,  with an interval of 15 days)
(C).
Calcineurin inhibitors, including CsA, TAC and sirolimus,
are targeted to T cells. Among these agents, TAC in partic-
ular has been used alone or in combination with MMF  in
the treatment of patients with RLN, mainly in small series
with patients of Asian origin. The results show a reduction
in proteinuria and beneﬁts in relation to extra-renal man-
ifestations, in addition to the possibility of its use during
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Table 5 – SBR recommendations for the treatment of refractory lupus nephritis, APSN, LN in pregnancy, pediatric LN and
management in ERF.
Recommendations Agreement
Refractory LN
LN should be considered refractory when CR or PR is not achieved after 12 months of an appropriate
treatment.
a)  1.0
Consider a new kidney biopsy to assist in identifying the cause of refractoriness and in therapeutic decision. a) 0.9;  b) 0.1
Rituximab is indicated, including cases with renal insufﬁciency. a) 1.0
Tacrolimus (alone or in combination with MMF) may be used as an alternative. a) 1.0
APSN associated to LN
Search aPl in patients with LN, due to the possibility of an association with APSN. a)  1.0
Maintain control of risk factors associated with vasoocclusive events in patients with aPl. a)  1.0
In patients with APSN, maintain INR close to 3 and consider the concomitant use of antiplatelet agents. a) 1.0
LN and pregnancy
SLE female patients should be advised not to become pregnant until disease remission for at least six months
and with a normal renal function.
a)  1.0
Pregnancy should be planned, including discontinuation of teratogenic medications (ARB, CY, coumarin, ACE
inhibitors, leﬂunomide, MMF and MTX).
a)  0.75; b) 0.25
Monitoring should be done by a multidisciplinary team throughout pregnancy and puerperium. a) 0.9;  b) 0.1
HCLQ should be used throughout pregnancy. a) 1.0
CS and AZA can be used during pregnancy. a) 1.0
LN in PSLE patients
The treatment of nephritis in PSLE patients is similar to that of adults, with dose adjustment of drugs
(AZA = 2.0–3.0 mg/kg/day, MP = 20–30; MMF = 30 mg/kg/day or 600 mg/m2 BSA/day); reinforce adherence at every
visit.
a) 1.0
LN and ERF
Maintain the treatment by a rheumatologist even after RRT, including the use of HCLQ with adjustment of its
doses.
a)  1.0
Extrarenal recurrences can be treated with CS, AZA and MMF (with adjusted doses). a) 1.0
Consider renal transplantation in patients with ERF (living or cadaver donor). a) 1.0
Special consideration should be given to patients with aPl, because of the risk of thrombosis in arteriovenous
ﬁstula and vasoocclusive lesions with potential graft loss.
a)  1.0
Agreement: the numbers in each recommendation express the percentages of agreement among the members, according to the classiﬁcation
used.
aPl, antiphospholipid antibodies; AZA, azathioprine; ARB, angiotensin receptor blockers; CY, cyclophosphamide; CS, corticosteroids; ERF, estab-
lished chronic kidney disease; ACEI, angiotensin-converting enzyme inhibitors; SLE, systemic lupus erythematosus; PSLE, pediatric SLE; MMF,
mycophenolate mofetil; MP, methylprednisolone; MTX, methotrexate; LN, lupus nephritis; APSN, nephropathy of APS; CR, complete remission;
repla
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ePR, partial remission; INR, international normalized ratio; RRT, renal 
regnancy (class C). However, its known diabetogenic effect
hould be taken into account, especially in patients with
etabolic syndrome, in addition to the thrombotic risk in
Pl positive patients (C).135–138 Belimumab, an anti-Blys anti-
ody, was not speciﬁcally evaluated in patients with LN, but
n the two main studies with this agent approximately 10%
f patients had GN with proteinuria of up to 6 g/day. In the
nalysis of this subgroup, the drug was effective in reduc-
ng the levels of proteinuria139,140; however, more  studies are
eeded to determine the efﬁcacy of belimumab in this condi-
ion (Table 5).141
ephritis  in  pediatric  systemic  lupus
rythematosus  (PSLE)n about 10–20% of patients with SLE, the onset of the dis-
ase occurs before reaching the age of 18, when the conditioncement therapy.
is classiﬁed as PSLE,142,143 characteristically showing greater
activity, cumulative damage and disease severity compared to
the adults. Additionally, these patients show high frequency
of nephritis (in up to 80% of patients), neurological and hema-
tological involvement and pulmonary hemorrhage.143–147
The treatment of nephritis in patients with PSLE is sim-
ilar to the treatment of adults, but the severity and poor
adherence determine a higher annual cost.148 For this rea-
son, in most centers of reference the current concept is that
one should emphasize adherence across all visits, particu-
larly in the case of adolescents.147 A consensus document
published in 2012 for induction therapy of lupus PGN in chil-
dren and adolescents suggested three regimens with CS: oral,
MP  pulse therapy, or a combination of these two.  However,
studies are lacking to determine which of these schemes
with CS is the most suitable for LN in the pediatric age
group.149 Prolonged exposure to corticosteroids should always
be avoided, reducing doses of prednisone to ≤10 mg/day
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between 4 and 6 months21 and discontinuation of this drug,
whenever possible. As is recommended for adult patients,
HCLQ (5.0–6.0 mg/kg/day) is indicated in all cases of PSLE
nephritis.21 NL class I or II is generally controlled by CS
and HCLQ. For class III or IV, induction therapy is indicated
with a combination of HCLQ, CS and an immunosuppressive
agent: CY IV (0.5–1.0 g/m2 BSA/month for 6 months) or MMF
(30 mg/kg/day or 600 mg/m2 BSA/day). Maintenance therapy
is suggested with AZA (2.0–3.0 mg/kg/day) or MMF.150 A con-
trolled study of LN in patients with PSLE suggests a therapeutic
response similar to that obtained in studies of adults with CY
or MMF.151 CY seems to have a better risk-beneﬁt proﬁle in
children and adolescents compared with adults,150 with rare
occurrences of primary ovarian failure (early menopause),152
besides facilitating adherence.149 The scheme with low doses
of CY (ET) has not been evaluated in the pediatric population.21
In cases of LN class V, drugs to reduce proteinuria – HCLQ, CS
and immunosuppressants (CY, MMF  or AZA) – are indicated,153
despite the absence of adequate prospective studies evaluat-
ing these agents in pediatric populations.
Therapy with RTX (375 mg/m2 BSA/week for 4 doses) has
been used in refractory nephritis in PSLE patients,154 but this
scheme still requires studies with a larger number of patients.
To date, there is still no study of belimumab in children and
adolescents with lupus (Table 5).
Established  chronic  kidney  disease  in  lupus
nephritis
Currently, about 10–29% of patients with NL develop ERF,
requiring renal replacement therapy (RRT).16 Data from the
United States Renal Data System (USRDS) show an increased
prevalence of LN as a cause of ERF, from 1.13 to 3.2% in the age
group 20–44 years, possibly related to an earlier deﬁnition of
diagnosis (USRDS 2011). As with in other countries, in Brazil
the mean age of patients with SLE at the onset of RRT is 38
years, much lower than that of patients with HBP (70 years),
diabetes mellitus type 1 (51 years) and DM type 2 (64 years)
(SBR 2014 census) (A).
Complication rates of ERF in SLE patients are similar to
other etiologies, but with higher frequency of ﬁstula loss.155
There is also the possibility of renal function recovery, which
may occur after the implementation of dialysis in up to 28%
of patients, usually in the ﬁrst 6 months of dialysis.156–158
Most patients remain in remission, but outbreaks of activ-
ity may occur.159–163 In fact, many  symptoms of ERF may be
confused with manifestations of SLE, such as fever, arthralgia,
arthritis, alopecia, retinal changes, headache, serositis, hema-
tological changes and reduced levels of complement fractions.
In this sense, non-renal SLEDAI score (SLEDAInr) which is
derived from SLEDAI, was validated as a useful instrument for
assessing activity in patients on RRT160,163,164; this tool can be
used in approaching those patients (B).  The survival of patients
with SLE in RRT at 5 years ranges from 50 to 89% and the
157,158,162,164–172mortality is typically multifactorial. Recently,
a prospective study showed an independent association of
disease activity at the start of RRT (with SLEDAInr >8) with
increased mortality at 5 years (B).9. 2 0 1 5;5 5(1):1–21
Both CS and HCLQ can be employed for RRT, but myelotoxic
drugs such as methotrexate and CY should be avoided. Other
drugs such as AZA and MMF should be evaluated individu-
ally. Doses of immunomodulatory medications should not be
corrected and do not require an additional dose after dialysis
of the drugs already mentioned. There is no evidence on the
safety of the use of immunobiologicals in SLE patients on dial-
ysis, but it is likely that in the event of such drugs are used,
there is no need of dosage readjustment, for these are high
molecular weight compounds not removable by dialysis mem-
branes (D).  All things considered, all SLE patients in RRT should
be monitored by the rheumatologist.
Renal transplantation (TxR) from cadaveric source has
proved a successful option since the 1950s, but its use
in patients with LN was questioned by the potential risk
of recurrence in the transplanted kidney. However, since
1975 it has been demonstrated that patients with SLE have
a behavior similar to other patients (Advisory Committee,
1975); and since that time, TxR procedures have been per-
formed with a very low frequency of recurrence.173–175 Factors
such as an association with APS or high aPl titles176,177 and
donor type178 contribute to worse results, but these are not
hindering factors to this procedure in these patients (C)
(Table 5).
Lupus  nephritis  and  pregnancy
The fertility rate in patients with SLE is considered normal;
however, severe renal failure and high doses of CS can cause
menstrual irregularities and amenorrhea.179 At the same time,
some immunosuppressants such as CY can induce ovarian
failure, and this complication depends on the patient’s age at
onset of medication, duration of treatment and, additionally,
the accumulated dose (D).180
Pregnancy in patients with SLE should be considered as
being a high-risk event; a multidisciplinary approach up to
puerperium is recommended. Studies report a two to threefold
increase in the frequency of disease activity during pregnancy
(C)181,182 and the occurrence of complications, especially in
women with moderate to severe disease (C).183
Women with SLE should be advised to avoid pregnancy
until the disease is in remission for at least six months
(D)184–186 and that GFR >50 mL/min.21 (D) Furthermore, the use
of improper medication for the period is avoided.187
The risk of obstetric and neonatal complication is higher in
women with SLE compared to the general population (A).188,189
However, in the last decades there has been a reduction from
43% (between 1965 and 1969) to 17% (between 2000 and 2003) in
fetal loss (D).190 The frequency of miscarriage is increased and
intrauterine fetal death is ﬁve times greater. Pre-eclampsia (PE)
occurs in over 20% versus 7.6% in the population without lupus;
on the other hand, intrauterine growth restriction (IUGR) is
also common, especially with pre-existing renal disease. Pre-
maturity affects up to 33% of pregnancies and is associated
with HBP, use of CS at the time of conception and during preg-
nancy, disease activity, and presence of nephrotic proteinuria
and aPl (C).188,191
The independent risk factors for pregnancy loss in the
cohort at Johns Hopkins Hospital were: proteinuria in 1st
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rimester, thrombocytopenia, APS and HBP (C).192 A systematic
eview on the outcome of pregnancy in patients with SLE,
hich included 1842 patients and 2751 pregnancies, identiﬁed
s main maternal complications: lupus activity (25.6%), HBP
16.3%), nephritis (16.1%), PE (7.6%) and eclampsia (0.8%). Fetal
omplications included abortion (16.0%), fetal death (3.6%),
eonatal death (2.5%) and IUGR (12.7%). The pregnancy fail-
re rate was 23.4% and that of preterm babies, 39.4%. The
eta-analysis showed a positive association between active
ephritis and prematurity, HBP and PE (D).193
The main risk factors for PE are current or previous LN,
E, lupus active at the time of conception, presence of native
nti-ds-DNA, low blood levels of complement, obesity and HBP
A).188,191,194–196
It is mandatory to differentiate activity of lupus from phys-
ologic changes of pregnancy, and activity of PE from activity of
L, since the therapeutic approach will be absolutely distinct:
mmunosuppression or interruption (D).196,197 This challenge
s even greater when these conditions coexist.
During pregnancy, the risk of LN reactivation goes from 20
o 30%186 and a multicenter study identiﬁed that LN increases
he risk of miscarriage, premature birth, PE and IUGR, but this
isease is not a contraindication for pregnancy, provided that
 careful planning of conception, monitoring and multidisci-
linary treatment occur (C).198 In a series of Brazilian female
atients with SLE, the frequency of fetal loss was signiﬁcantly
igher in those patients with LN and aPl (37%) and also in
hose with LN but without aPl (26.6%) compared to patients
oth without LN and aPl (12.2%) (C).199
A literature review conducted between 1962 and 2009 iden-
iﬁed that all maternal deaths during pregnancy in patients
ith LN occurred during disease activity and showed a corre-
ation with infection (41.2%) or lupus complications (29.4%) (D)
Table 5).200
LE  therapy  in  pregnancy
regnancy in a patient with SLE does not require any speciﬁc
reatment (D)20,21; however, if the woman is being treated with
CLQ before conception, this agent should be continued dur-
ng pregnancy, because it reduces the chance of reactivation
nd possibly also the incidence of neonatal lupus. NSAIDs
hould not be used in female patients with LN; these drugs
ncrease the risk of miscarriage, premature ductus arteriosus
losure and prolonged labor (D).196,201
Given that prednisone suffers placental inactivation, this
s the preferred CS for use in this period (D).202 Fluorinated
S, as dexamethasone and betamethasone, cross the placen-
al barrier and should be used to induce fetal lung maturation
n premature births (D).203
Prednisone should be used according to the seriousness of
ymptoms (D),204 but in doses >20 mg/day this medication is
ssociated with gestational diabetes, HBP, PE and premature
upture of membranes.191 When CS are used in the pericon-
eption period, these drugs are associated with a 1.7-fold
205ncrease in the risk of cleft lip and palate (D).
AZA (≤2 mg/kg/day) is considered safe during pregnancy,
lthough this drug has been associated with IUGR and with
igher rates of pregnancy loss (D).201 0 1 5;5 5(1):1–21 15
Due to the increased risk of thrombosis in women with
NS, the use of low-dose aspirin (100 mg/day) is indicated
throughout pregnancy, regardless of the presence of aPl.188
Methotrexate, CY, MMF,  leﬂunomide, ACEI, ARB and coumarin
are considered drugs with proven teratogenic risk (D)201,202,205;
thus, ideally these agents should be discontinued at least 3
months before conception (Table 5).
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